Infocus interview with CEO Helen Tuvesson at Redeye Growth Day 2023, May 30
June 3, 2024
Presentations
Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis, audiocast summary
December 1, 2023
financialhearings.com – audiocast, the clinical plan and positioning of tasquinimod in myelofibrosis
December 1, 2023
Active Biotech: CEO Helén Tuvesson presents at Redeye Life Science Day 2023 – 23 November
November 27, 2023
Redeye video interview with CEO Helén Tuvesson (in Swedish)
November 16, 2023
Active Biotech presentation at Aktiespararnas “Aktiedag Lund”, October 9, 2023 (in Swedish)
October 10, 2023
CEO Helene Tuvesson presents at Redeye Fight Cancer 2023
January 23, 2023
Infocus interview with CEO Helén Tuvesson at Redeye Life Science Day 2022 (in Swedish)
November 29, 2022
Active Biotech presentation at Aktiespararnas “Aktiedagen Lund”, September 26, 2022 (in Swedish)
September 27, 2022
Redeye interview with CEO Helén Tuvesson (in Swedish)
August 22, 2022
Active Biotech presentation at Aktiespararnas “Aktiedag Lund” (in Swedish)
September 28, 2021
Active Biotech’s presentation at “Aktiedagen” May 4, 2021 (Swedish shareholders’ association, in Swedish)
May 4, 2021
“Hur bygger man ett lönsamt Life Science-bolag? – Aktiedagen” January 27, 2021 (in Swedish)
January 27, 2021
Laquinimod – Treatment of Inflammatory Eye Disorders
November 24, 2020
Laquinimod – Treatment of Inflammatory Eye Disorders (PDF)
November 24, 2020
Tasquinimod – Treatment of Multiple Myeloma
November 24, 2020
Tasquinimod – Treatment of Multiple Myeloma (PDF)
November 24, 2020
An Introduction to Multiple Myeloma
November 24, 2020
An Introduction to Multiple Myeloma (PDF)
November 24, 2020
A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma
November 24, 2020
A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma (PDF)
November 24, 2020
Capital Markets Day 2020
November 24, 2020